Dr. Rana McKay on Second-line Therapy and Beyond for Metastatic RCC

In Part 3 of this video series, Rana McKay, MD, Medical Oncologist and Associate Professor of Medicine, UC San Diego Health, offers an overview of the second-line and later-line therapy options after progression on first-line treatment for metastatic RCC.

The best data available of patients who have received prior immunotherapy and then subsequent therapy comes from the CANTATA study, which looked at the combination of cabozantinib plus telaglenastat versus cabozantinib alone.

View Dr. McKay’s other comments on advanced RCC management, including the Current Treatment Paradigm, Frontline Immunotherapy, Novel Therapies and Sequences, and Radiation Therapy and Radiopharmaceuticals.